Reliable autologous expression of recombinant human proteins - from gene sequence to the expressed and purified protein - in human or CHO cells is essential for many aspects of biomedical research and drug development, but often hampered by low expression yields limiting subsequent structural and functional analyses.

Thermo Fisher Scientific’s complete portfolio from Invitrogen™ GeneArt™ gene synthesis to advanced expression systems provides researchers the unique ability to optimize their gene expression results. Our proprietary sequence optimization GeneOptimizer™ algorithm improves the sequence via a parallel multi-parameter approach. To further maximize the protein yield, you can choose between our best-in-class serum free Gibco™ FreeStyle™ or Invitrogen™ Expi293™ and ExpiCHO™ expression host systems.

This holistic approach is the most efficient way to streamline your gene-to-protein workflow for maximal performance, either by purchasing reagents for in-house work or by outsourcing the complete workflow as a highly customized service offered by the GeneArt™ Protein Team.

The talk will explain the basis of gene synthesis and optimization and how the combination with the best expression system generates unmatched expression reliability and protein yields. This approach is highly advantageous early on during drug development to minimize changes in protein quality/function when moving from R&D to bioproduction.